Mineralocorticoid receptor antagonist spironolactone prevents pig serum-induced hepatic fibrosis in rats

Translational Research

Volumn 148, Issue 3, 2006, Pages 149-156

  Fujisawa, Genro ^a   Muto, Shigeaki ^a   Okada, Koji ^a   Kusano, Eiji ^a   Ishibashi, Shun ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ALPHA SMOOTH MUSCLE ACTIN; HYDROXYPROLINE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; SODIUM PROTON EXCHANGE PROTEIN 1; SPIRONOLACTONE;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL; LIVER FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN; STAINING; STATISTICAL SIGNIFICANCE; STELLATE CELL; SWINE;

EID: 33747851971     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2006.03.007     Document Type: Article

References (34)

1. Iredale J. Cirrhosis. new research provides a basis for rational and targeted treatments. Brit Med J 327 (2003) 143-147
2. Eng F.J., and Freidman S.L. Fibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex. Am J Physiol 279 (2000) G7-G11
3. Friedman S.L., Roll J.F., Boyles J., and Bissell D.M. Heparic lipocytes. the principle collagen producing cells of normal rat liver. Proc Natl Acad Sci USA 82 (1985) 8681-8685
4. Yokoi Y., Namihisa T., Kuroda H., Komatsu I., Miyazaki A., Watanabe S., et al. Immunocytochemical detection of desmin in fat-storing cells (Ito cells). Hepatology 4 (1984) 709-714
5. Baroni G.S., D'Ambrosio L., Curto P Casini A., Mancini R., Jezequel A.M., et al. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 23 (1996) 1189-1199
6. Geerts A., Lazou J.M., De Bleser P., and Wisse E. Tissue distribution, quantitation and proliferation kinetics of fat-storing cells in carbon-tetrachloride-injured rat liver. Hepatology 13 (1991) 1193-1202
7. Mak K.M., Leo M.A., and Lieber C.S. Alcholic liver injury in baboons. transformation of lipocytes to transitional cells. Gastroenterolgy 87 (1984) 188-200
8. Kent G., Gay S., Inohue T., Bahu R., Minick O.T., and Popper H. Vitamin A-containing lipocytes and formation of type III collagen in liver injury. Proc Natl Acad Sci USA 73 (1976) 3719-3722
9. Ramos S.G., Montenegro A.P., Goissis G., and Rossi M.A. Captopril reduces collagen and mast cell and eosinophil accumulation in pig serum-induced rat liver fibrosis. Pathology Intern 44 (1994) 655-661
10. Jonsson J.R., Clouston A.D., Ando Y., Kelemen L.I., Horn M.J., Adamson M.D., et al. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121 (2001) 148-155
11. Yoshiji H., Kuriyama S., Yoshii J., Ikenaka Y., Noguchi R., Nakatani T., et al. Angiotensin-II type I receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34 (2001) 745-750
12. Zaini A., Pearce P., and Funder J.W. High affinity aldosterone binding in rat liver-a re-evaluation. Clin Exp Pharmacol Physiol 14 (1987) 39-45
13. Yang X., Li X., Wu P., Meng Y., Li S., and Lai W. CYP11B2 expression in rat liver and the effect of spironolactone on hepatic fibrogenesis. Horm Res 53 (2000) 288-293
14. + exchanger, NHE1. structure, regulation, and cellular actions. Annu Rev Pharmacol Toxicol 42 (2002) 527-552
15. Caligiuri A., De Franco R.M.S., Romanelli R.G., Gentilini A., Meucci M., Failli P., et al. Antifibrogenic effects of canrenone, an antialdosteronic drug, on human hepatic stellate cells. Gastroenterology 124 (2003) 504-520
16. + exchanger reduces rat hepatic stellate cell activity and liver fibrosis. an in vitro and in vivo study. Gastroenterolgy 120 (2001) 545-556
17. + exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 37 (2003) 256-266
18. Di Sario A., Baroni G.S., Bendia E., D'Ambrosio L., Ridolfi F., Marileo J.R., et al. Characterization of ion transport mechanisms regulating intracellular pH in hepatic stellate cells. Am J Physiol 273 (1997) G39-G48
19. + exchanger modulates the fibrogenic effect of oxidative stress in hepatic stellate cells. J Hepatol 30 (1999) 868-875
20. + exchange activation by platelet-derived growth factor in rat hepatic stellate cells. Gastroenterology 116 (1999) 1155-1166
21. Fujisawa G., Okada K., Muto S Fujita N., Itabashi N., Kusano E., et al. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury. Hypertension 41 (2003) 493-498
22. Fujisawa G., Okada K., Muto S., Fujita N., Itabashi N., Kusano E., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Intern 66 (2004) 1493-1502
23. Young M., Fullerton M.J., Dilley R., and Funder J.W. Mineralocorticoid, hypertension and cardiac fibrosis. J Clin Invest 93 (1994) 2578-2583
24. + exchanger in vascular smooth muscle cells by nongenomic and genomic mechanisms. Kidney Intern 56 (1999) 1400-1412
25. + exchange in isolated rat hepatocytes. Eur J Biochem 187 (1990) 677-682
26. + exchange is activated early, transiently and at a posttranscriptional level during rat liver regeneration. Hepatology 19 (1994) 1290-1301
27. + exchange is activated at transcriptional and posttranscriptional levels in rat biliary cirrhosis. Gastroenterology 107 (1994) 468-478
28. Hatakeyama H., Miyamori I., Fujita T., Takeda Y., Takeda R., and Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269 (1994) 24316-24320
29. Silvestre J.S., Heymes C., Oubenaissa A., Robert V., Aupetit-Faisant B., Carayon A., et al. Activation of cardiac aldosterone production in rat myocardial infarction. Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99 (1999) 2694-2701
30. Perez-Ayuso R.M., Arroyo V., Planas R., Gaya J., Bory F., Rimola A., et al. Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of renin-aldosterone system. Gastroenterology 84 (1983) 961-968
31. Angeli P., Dalla Pria M., De Bei E., Albino G., Caregaro L., Merkel C., et al. Randomized clinical study of the efficacy of amilolide and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 19 (1994) 72-79
32. Lacolley P., Safar M.E., Lucet B., Ledudal K., Labat C., and Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol 37 (2001) 662-667
33. Virdis A., Neves M.F., Amiri F., Viel E., Touyz R.M., and Schiffrin E.L. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension 40 (2002) 504-510
34. Meric G., Dallemagne C., Endre Z., Margolin S., Taylor S.M., and Brown L. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. Brit J Pharmacol 133 (2001) 687-694